Adelaide Research & Scholarship: Search

Search

Results 1-8 of 8 (Search time: 0.002 seconds).

previous
1
next

Item hits:

Preview	Issue Date	Title	Author(s)
	2008	Is drug treatment superior to allografting as first-line therapy in chronic myeloid leukemia?	Hughes, T.
	2008	Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia	le Coutre, P.; Ottmann, O.; Giles, F.; Kim, D.; Cortes, J.; Gattermann, N.; Apperley, J.; Larson, R.; Abruzzese, E.; O'Brien, S.; Kuliczkowski, K.; Hochhaus, A.; Mahon, F.; Saglio, G.; Gobbi, M.; Kwong, Y.; Baccarani, M.; Hughes, T.; Martinelli, G.; Radich, J.; et al.
	2008	Current and emerging tests for the laboratory monitoring of chronic myeloid leukaemia and related disorders	Ross, D.; Hughes, T.
	2008	International standardisation of quantitative real-time RT-PCR for BCR-ABL	Cross, N.; Hughes, T.; Hochhaus, A.; Goldman, J.
	2008	BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros	Mullighan, C.; Miller, C.; Radtke, I.; Philips, L.; Dalton, J.; Ma, J.; White, D.; Hughes, T.; Le Beau, M.; Pui, C.; Relling, M.; Shurtleff, S.; Downing, J.
	2008	Optimizing outcomes for patients with advanced disease in chronic myelogenous leukemia	Giles, F.; DeAngelo, D.; Baccarani, M.; Deininger, M.; Guilhot, F.; Hughes, T.; Radich, J.; Ottmann, O.; Cortes, J.
	2008	Dasatinib cellular uptake and efflux in chronic myeloid leukemia cells: therapeutic implications	Hiwase, D.; Saunders, V.; Hewett, D.; Frede, A.; Zrim, S.; Dang, P.; Eadie, L.; To, L.; Vaz de Melo, J.; Kumar, S.; Hughes, T.; White, D.
	2008	Reverse transcription with random pentadecamer primers improves the detection limit of a quantitative PCR assay for BCR-ABL transcripts in chronic myeloid leukemia: Implications for defining sensitivity in minimal residual disease	Ross, D.; Watkins, D.; Hughes, T.; Branford, S.